 |
MultiVu Video Feed: WOMEN WITH A HEREDITARY RISK OF BREAST AND OVARIAN CANCER ARE ENCOURAGED TO GET TESTED - THOSE WITH AN ALTERED BRCA1 OR BRCA2 GENE HAVE A 56 TO 87 PERCENT RISK TO DEVELOP BREAST CANCER BY AGE 70
Sep 23, 2008
|
9.8 KB |
|
| |
Sept 23, 2008 /PRNewswire via COMTEX News Network/ -- **September is Ovarian Cancer Awareness Month** **October is Breast Cancer Awareness Month**
According to the American Cancer Society, more than 200,000 women in the U.S. will be diagnosed with breast or ovarian cancer this year. An estimated one in ten of these cases will be due to an inher...
|
|
Myriad Genetics Announces Topline Results of Phase 1 Trial of Vivecon for HIV
Sep 17, 2008
|
12.1 KB |
|
| |
SALT LAKE CITY, UT, Sep 17, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it has successfully completed dose escalation in the Phase 1 human clinical trial of Vivecon(TM), its HIV viral maturation inhibitor, in healthy volunteers. The trial demonstrated a favorable safety pr...
|
|
Myriad Genetics Board Explores Prospect of Separating Diagnostic and Pharmaceutical Businesses
Sep 11, 2008
|
9.4 KB |
|
| |
SALT LAKE CITY, UT, Sep 11, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that its Board of Directors is reviewing management's analysis of several strategic alternatives for the Company and is carefully considering these alternatives.
"The Board is committed to growing both of our business o...
|
|
Myriad Genetics Announces Fourth Quarter and Year-End Fiscal 2008 Financial Results Conference Call
Aug 19, 2008
|
7.2 KB |
|
| |
SALT LAKE CITY, UT, Aug 12, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) has arranged a conference call
with the management team to provide a company update. Peter D.
Meldrum, President and Chief Executive Officer, will host the call
along with Jim Evans, Chief Financial Officer, Gregory C.
Critchfield, M.D...
|
|
Myriad Genetics Reports Financial Results for Fiscal 2008
Aug 19, 2008
|
17.2 KB |
|
| |
SALT LAKE CITY, UT, Aug 19, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today reported financial
results for its fourth quarter and fiscal year ended June 30, 2008.
Molecular diagnostic product revenues for fiscal 2008 increased to a
record $222.9 million from $145.3 million for fiscal 2007, an increase
...
|
|
Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan™ in Alzheimer's Disease
Jun 30, 2008
|
5.2 KB |
|
| |
SALT LAKE CITY, UT, Jun 30, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced results of the
Act-Earli-AD trial, an 18-month Phase 3 study of Flurizan
(tarenflurbil) in patients with mild Alzheimer's disease. The study
did not achieve statistical significance on either of its primary
endpoints --...
|
|
Myriad Genetics' Alzheimer's Disease Drug Mechanism of Action Detailed in Nature Article
Jun 11, 2008
|
7.2 KB |
|
| |
SALT LAKE CITY, UT, Jun 11, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that the
mechanism of action of Flurizan® (tarenflurbil) -- its drug
candidate for the treatment of Alzheimer's disease, is elucidated in
the scientific journal Nature. The article, ...
|
|
Myriad Genetics Selects Lundbeck as European Partner for Flurizan
May 22, 2008
|
9.5 KB |
|
| |
SALT LAKE CITY, UT, May 22, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) today
announced the selection of H. Lundbeck A/S for European
commercialization of Flurizan®, Myriad's lead therapeutic candidate
for the treatment of Alzheimer's disease.
Myria...
|
|
Myriad Genetics Reports Results for Third Quarter of Fiscal 2008
May 6, 2008
|
13.3 KB |
|
| |
SALT LAKE CITY, UT, May 06, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) today reported
consolidated financial results for the third quarter of fiscal 2008
and the nine months ended March 31, 2008.
Molecular diagnostics revenue for the third quarter of fiscal 2008
was $59.0 million, comp...
|
|
Myriad Genetics Announces Third Quarter Fiscal 2008 Financial Results Conference Call
Apr 23, 2008
|
3.9 KB |
|
| |
SALT LAKE CITY, UT, Apr 23, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) has arranged a conference call
with the management team to provide a company update. Peter D.
Meldrum, President and Chief Executive Officer, will host the call
along with Jim Evans, Chief Financial Officer; Gregory C.
Critchfield, M.D...
|
|
Myriad Genetics to Present at Cowen Health Care Conference on March 18, 2008
Mar 6, 2008
|
3.7 KB |
|
| |
SALT LAKE CITY, UT, Mar 06, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN), announced today that Adrian
Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc., is
scheduled to present an overview of the Company at the 28th Annual
Cowen Health Care Conference, at 10:15 a.m. on March 18, at the
Boston Marriot...
|
|
Myriad Genetics to Present at the Lehman Brothers Healthcare Conference on March 19, 2008
Mar 6, 2008
|
3.7 KB |
|
| |
SALT LAKE CITY, UT, Mar 06, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN), announced today that Peter
Meldrum, President and CEO, is scheduled to present an overview of
the Company at the 11th Annual Lehman Brothers Global Healthcare
Conference, at 9:30 a.m. on March 19, at the Loews Miami Beach Hotel
in So...
|
|
Myriad Genetics Reports Results for Second Quarter of Fiscal 2008
Feb 5, 2008
|
11.2 KB |
|
| |
SALT LAKE CITY, UT, Feb 05, 2008 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today reported financial
results for the second quarter of fiscal 2008 and the six months
ended December 31, 2007.
For the second quarter of fiscal 2008, molecular diagnostics revenue
increased by 55%, to $53.1 million, from $34.2 m...
|
|
Myriad Genetics Announces Completion of Phase 1 Trial of Anti-Thrombin Drug MPC-0920
Jan 29, 2008
|
9.6 KB |
|
| |
Salt Lake City, UT, Jan 29, 2008—Myriad Genetics, Inc. (NASDAQ: MYGN) has completed a Phase 1 human
clinical trial of MPC-0920, an orally available, direct thrombin
inhibitor. The trial studied healthy volunteers in a single,
escalating dose ...
|
|
Myriad Genetics, Inc. Expands Commercial and Clinical Infrastructure
Jan 23, 2008
|
9.9 KB |
|
| |
Salt Lake City, UT, Jan 23, 2008—Myriad Genetics, Inc. (NASDAQ: MYGN) has expanded its commercial and
clinical capabilities, the Company said today. Myriad recently named
Robert Rubens, M.D., as Vice President of Medical Affairs, and James
DeMarco as Vice President of Sales for Myriad Pharmaceutical...
|
|
Myriad Genetics Announces Second Quarter Fiscal 2008 Financial Results Conference Call
Jan 22, 2008
|
4.3 KB |
|
| |
Salt Lake City, UT, Jan 22, 2008—Myriad Genetics, Inc. (NASDAQ: MYGN) has arranged a conference call
with the management team to provide a company update. Peter D.
Meldrum, President and Chief Executive Officer, will host the call
along with Jim Evans, Chief Financial Officer; Gregory C.
Critchfiel...
|
|
Myriad Genetics Submits IND on Vivecon
Dec 4, 2007
|
11.8 KB |
|
| |
Salt Lake City, UT, December 04, 2007—Myriad Genetics, Inc. (NASDAQ:
MYGN) announced today that it has
submitted an Investigational New Drug (IND) application to the United
States Food and Drug Administration to begin human clinical trials
with its drug candidate, ...
|
|
Myriad Genetics Elects Gerald P. Belle to Its Board of Directors
Nov 27, 2007
|
6.1 KB |
|
| |
Salt Lake City, UT, Nov 27, 2007—Myriad Genetics, Inc. (NASDAQ:
MYGN) announced today that it has
elected Gerald P. (Jerry) Belle to its board of directors. Mr.
Belle's term is effective as of November 15, 2007.
Mr. Belle was pr...
|
|
Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2008
Nov 1, 2007
|
11.9 KB |
|
| |
Salt Lake City, UT, Nov 01, 2007—Myriad Genetics, Inc. (NASDAQ: MYGN) today reported financial
results for the first quarter of fiscal 2008. For the three-month
period ended September 30, 2007, molecular diagnostic revenue
increased to $46.1 million from $30.9 million in the same three
months in 20...
|
|
Myriad Genetics Sponsors Dance-Theater Event Hosted by Alzheimer's Association, New York City Chapter
Oct 30, 2007
|
5.9 KB |
|
| |
SALT LAKE CITY, UT, Oct 30, 2007—Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced
today that it is sponsoring a unique dance-theater event titled,
"Demolition Derby: when a mind loses its license to drive," hosted by
the Alzheimer's Association, Ne...
|
|
|
